{"schema_version":"secwatch.filing_event.v1","accession":"0001823239-22-000008","form_type":"8-K","ticker":"MRVI","cik":"0001823239","company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","filed_at":"2022-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.535783+00:00","generated_at":"2026-06-27T05:36:55.019129+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Maravai Q4 revenue $228M, up 132% YoY; net income $127M; 2022 guidance raised to $920-960M","bullets":["Q4 revenue $228.4M (+132% YoY); net income $127.1M (+778% YoY).","FY2021 revenue $799.2M (+181% YoY); net income $469.3M; adjusted EBITDA $582.8M.","Nucleic Acid Production segment Q4 revenue $212.5M (+173% YoY) driven by CleanCap demand for mRNA vaccines.","2022 revenue guidance raised to $920M-$960M, implying 15-20% growth over 2021 record.","Completed debt repricing saving ~$6.8M annually in interest; acquired MyChem for ultra-pure nucleotides."],"urls":{"canonical":"https://secwatch.observer/filing/0001823239-22-000008","json":"https://secwatch.observer/filing/0001823239-22-000008.json","markdown":"https://secwatch.observer/filing/0001823239-22-000008.md","text":"https://secwatch.observer/filing/0001823239-22-000008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1823239/000182323922000008/0001823239-22-000008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1823239/000182323922000008/mrvi-20220223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T05:36:55.019129+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}